Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash & Equivalents (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Cash & Equivalents for 11 consecutive years, with $65.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 8.5% to $65.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.3 million through Dec 2025, down 8.5% year-over-year, with the annual reading at $65.3 million for FY2025, 8.5% down from the prior year.
  • Cash & Equivalents hit $65.3 million in Q4 2025 for Voyager Therapeutics, up from $45.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $268.3 million in Q1 2023 to a low of $43.9 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $107.5 million across 5 years, with a median of $97.9 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: surged 211.88% in 2023 and later plummeted 68.84% in 2024.
  • Year by year, Cash & Equivalents stood at $117.4 million in 2021, then fell by 15.73% to $99.0 million in 2022, then plummeted by 30.47% to $68.8 million in 2023, then grew by 3.73% to $71.4 million in 2024, then decreased by 8.5% to $65.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for VYGR at $65.3 million in Q4 2025, $45.1 million in Q3 2025, and $43.9 million in Q2 2025.